Arrhythmia substrate and management in hypertrophic cardiomyopathy: From molecules to implantable cardioverter-defibrillators

European Heart Journal, Supplement

Volumn 3, Issue L, 2001, Pages

  Janse, Michiel J ^a,c   De Bakker, J M T ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Abnormal gap junction distribution; Delayed afterdepolarizations; Fibrosis; Re entry; Triggered activity

Indexed keywords

MITOCHONDRIAL DNA; TROPONIN T;

ANIMAL MODEL; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; DEFIBRILLATOR; EXERCISE; GAP JUNCTION; GENE MUTATION; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE FIBROSIS; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; RAT; SUDDEN DEATH;

EID: 0035149876     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90059-8     Document Type: Article

References (48)

1. Hypertrophic cardiomyopathy
2. Asymmetrical hypertrophy of the heart in young adults
3. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: Echocardiographic analysis of 4111 subjects in the CARDIA study
4. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk
5. Hypertrophic cardiomyopathy: An important cause of sudden death
6. Prognosis in hypertrophic cardiomyopathy observed in a large clinical population
7. The management of hypertrophic cardiomyopathy
8. Sudden death in children and adolescents
9. Sudden death in young athletes
10. Task Force II: Hypertrophic cardiomyopathy, other myopericardial diseases and mitral valve prolaps
11. Familial hypertrophic cardiomyopathy. From mutations to functional defects
12. The molecular genetic basis for hypertrophic cardiomyopathy
13. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy
14. Sudden death due to troponin T mutations
15. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy
16. Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death
17. Transgenic rat hearts expressing a human cardiac troponin T deletion reveal diastolic dysfunction and ventricular arrhythmias
18. Familial hypertrophic cardiomyopathy: Cornering the rat
19. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy
20. Electrophysiological abnormalities and arrhythmias in alpha MHC mutant familial hypertrophic cardiomyopathy mice
21. A transgenic rabbit model for human hypertrophic cardiomyopathy
22. Hypertrophic cardiomyopathy: Pathology and pathogenesis
23. Hypertrophic cardiomyopathy without hypertrophy: Two families with myocardial disarray in the absence of increased myocardial mass
24. Altered patterns of cardiac intercellular junction distribution in hypertrophic cardiomyopathy
25. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings
26. Myocardial metabolic, hemodynamic and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy
27. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy
28. Sudden death in hypertrophic cardiomyopathy: Potential importance of altered autonomic control of vasculature
29. Prospective assessment of blood pressure response as a marker of risk of sudden death in hypertrophic cardiomyopathy
30. Prognostic value of nonsustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population
31. Electrophysiological investigation of patients with hypertrophic cardiomyopathy. Evidence that slowed intraventricular conduction is associated with an increased risk of sudden death
32. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
33. Sudden death in hypertrophic cardiomyopathy: A profile in 78 patients
34. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
35. Mechanisms of arrhythmias in heart failure
36. Heart failure: The electrophysiological connection
37. Arrhythmias in heart failure: Current concepts of mechanism and therapy
38. The Xth Gordon K. Moe lecture. Arrhythmogenesis in heart failure
39. Triggered activity and automaticity in ventricular trabeculae of failing human and rabbit hearts
40. Electrophysiologic and extracellular ionic changes during acute ischemia in failing and normal rabbit myocardium
41. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: Electrophysiologic and anatomic correlation
42. Macroreentry in the infarcted human heart: The mechanisms of ventricular tachycardias with a 'focal' activation pattern
43. Slow conduction in the infarcted human heart. 'Zigzag' course of activation
44. Fractionated electrograms in dilated cardiomyopathy: Origin and relation to abnormal conduction
45. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. A prospective study
46. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
47. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment